According to the meta-analysis by Kim et al., immunotherapy considerably increased overall survival compared to chemotherapy in pretreated KRAS-mutated NSCLC patients, except for individuals with wild-type KRAS [138]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.